Cotargeting of Androgen Synthesis and Androgen Receptor Expression as a Novel Treatment for Castration-Resistant Prostate Cancer
Technical Report,01 Aug 2018,31 Jul 2019
Purdue University West Lafayette United States
Pagination or Media Count:
Prostate cancer is the third leading cause of cancer death among American men in 2017. The majority of the death is due to the development of castration resistant prostate cancer CRPC after androgen deprivation therapy ADT. Despite the development and use of next generation anti-AR signaling inhibitors ASI such as abiraterone and enzalutamide, resistance to ASI remains the major clinical challenge. The proposed research is based on the finding that protein arginine methyltransferase 5 PRMT5 is a novel epigenetic activator of AR transcription. If PRMT5 targeting can inhibit or eliminate AR transcription, combining PRMT5 targeting with androgen synthesis inhibition should exhibit a better treatment effect for CRPC. During the past grant period, we have pICln as a novel cofactor to cooperate with PRMT5 to epigenetically activate AR expression and promote the growth of CRPC cells in vitro and xenograft tumors in mice. We will continue to extend this novel finding and complete proposed animal experiments in Aim 3 using a novel PRMT5 inhibitor during next grant period.
- Medicine and Medical Research